Table 6.
ANOVA-derived maximum observed S-(−)-ALA enantiomer geometric LS mean plasma concentrations (Cmax) and the corresponding 95% CI by sex (12 males/12 females) and treatment
| S-(−) Cmax LS means and CI Male subjects (N=12)
|
S-(−) Cmax LS means and CI Female subjects (N=12)
|
|||||
|---|---|---|---|---|---|---|
| Treatment | Geometric mean (ng · mL−1) | 95% CI
|
Geometric mean (ng · mL−1) | 95% CI
|
||
| Lower | Upper | Lower | Upper | |||
| OS | 3,500.7 | 2,474.7 | 4,952.0 | 4,094.3 | 3,401.3 | 4,928.5 |
| T 200 | 1,521.6 | 990.4 | 2,337.9 | 1,934.9 | 1,446.7 | 2,587.9 |
| T 300 | 1,782.3 | 1,137.5 | 2,792.6 | 1,913.1 | 1,242.1 | 2,946.5 |
| T 600 | 1,181.5 | 788.9 | 1,769.3 | 1,673.0 | 1,252.8 | 2,234.2 |
Abbreviations: ANOVA, analysis of variance; ALA, alpha-lipoic acid; LS, least squares; Cmax, maximum observed plasma concentration; CI, confidence interval; N, number; OS, orally administered ALA solution; T 200, 200 mg tablet; T 300, 300 mg tablet; T 600, 600 mg tablet.